Last edition
News about "Phase 3 pelacarsen tria"
Novartis Reports Phase 3 Results for Pelacarsen in Cardiovascular Disease
Novartis reports phase 3 Lp(a)HORIZON topline results for pelacarsen, an investigational ASO targeting Lp(a) production in patients with cardiovascular disease (CVD).
Phase 3 Pelacarsen Tria | 05/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members